Schering/Novo end diabetes agreement
Executive Summary
Companies terminate co-promotion agreement for Novo's oral antidiabetic Prandin and its insulin line, effective March 31. The agreement was signed in January 1998 for Prandin's launch, "but the market performance of Prandin is not sufficient for both parties to continue together," Novo said. Worldwide sales were $98 mil. in 1999